Checkpoint Therapeutics Inc (NASDAQ: CKPT) is 26.25% higher on its value in year-to-date trading and has touched a low of $1.38 and a high of $4.50 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CKPT stock was last observed hovering at around $4.02 in the last trading session, with the day’s gains setting it 0.02%.
Currently trading at $4.04, the stock is 0.37% and 12.92% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.33 million and changing 0.50% at the moment leaves the stock 31.88% off its SMA200. CKPT registered 134.88% gain for a year compared to 6-month gain of 59.37%. The firm has a 50-day simple moving average (SMA 50) of $3.5779 and a 200-day simple moving average (SMA200) of $3.06345.
The stock witnessed a 0.75% loss in the last 1 month and extending the period to 3 months gives it a 21.32%, and is 1.25% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 0.90% over the week and 0.97% over the month.
Checkpoint Therapeutics Inc (CKPT) has around 24 employees, a market worth around $338.41M and $0.04M in sales. Fwd P/E is 3.58. Profit margin for the company is -137170.73%. Distance from 52-week low is 192.75% and -10.22% from its 52-week high.
The EPS is expected to grow by 82.04% this year
76.0 institutions hold shares in Checkpoint Therapeutics Inc (CKPT), with institutional investors hold 28.35% of the company’s shares. The shares outstanding are 83.76M, and float is at 62.05M with Short Float at 8.10%. Institutions hold 24.22% of the Float.
The top institutional shareholder in the company is ARMISTICE CAPITAL, LLC with over 2.51 million shares valued at $5.39 million. The investor’s holdings represent 6.8608 of the CKPT Shares outstanding. As of 2024-06-30, the second largest holder is GEODE CAPITAL MANAGEMENT, LLC with 0.3 million shares valued at $0.65 million to account for 0.8292 of the shares outstanding. The other top investors are B. RILEY WEALTH ADVISORS, INC. which holds 0.23 million shares representing 0.6275 and valued at over $0.49 million, while BLACKROCK INC. holds 0.5554 of the shares totaling 0.2 million with a market value of $0.44 million.
Checkpoint Therapeutics Inc (CKPT) Insider Activity
The most recent transaction is an insider sale by Oliviero James F III, the company’s CEO, President and Director. SEC filings show that Oliviero James F III sold 15,090 shares of the company’s common stock on Apr 02 ’25 at a price of $4.04 per share for a total of $60964.0. Following the sale, the insider now owns 3.76 million shares.
Checkpoint Therapeutics Inc disclosed in a document filed with the SEC on Apr 01 ’25 that GRAY WILLIAM GARRETT (Chief Financial Officer) sold a total of 12,322 shares of the company’s common stock. The trade occurred on Apr 01 ’25 and was made at $4.05 per share for $49904.0. Following the transaction, the insider now directly holds 1.45 million shares of the CKPT stock.
Still, SEC filings show that on Feb 10 ’25, Oliviero James F III (CEO, President and Director) disposed off 10,331 shares at an average price of $3.15 for $32543.0. The insider now directly holds 3,775,019 shares of Checkpoint Therapeutics Inc (CKPT).
